NEWSROOM | Galderma

AAD 2023: Late-Breaking Phase III results demonstrate nemolizumab’s significant impact on prurigo nodularis

AAD 2023: Extensive updates from Galderma’s broad and innovative portfolio through posters and presentation sessions

Cetaphil Celebrates Global Initiative Highlighting Sensitive Skin with a Month of Skin Science Education

Galderma delivers strong FY 2022 growth driven by innovation and commercial performance

Cetaphil® unveils digital AI skin analysis tool to empower and educate users with sensitive skin

Cetaphil raises awareness of the connection between clothing and sensitive skin

Galderma Launches Cutting-Edge Formulation With Alastin Skincare® Resurface Skin Polish Developed To Uncover Visibly Glowing Skin

Galderma announces the launch of FACE by Galderma™ – a game-changing augmented reality solution helping healthcare professionals grow their activity and improve patient satisfaction

Galderma expands footprint with new Global Capability Center in Barcelona to support global growth

IMCAS 2023: Galderma to share latest data demonstrating high aesthetic improvement and patient satisfaction across its innovative portfolio

"The Full Spectrum of Dermatology: A Diverse And Inclusive Atlas" Launches New, Free Online Image Gallery

Galderma, the pure-play dermatology category leader and maker of Cetaphil, celebrates grand opening of U.S. headquarters in Dallas

Sales data confirm Galderma’s range of anti-acne products is the No.1 choice globally